{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-352679","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2021-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.934792+00:00","generated_at":"2026-06-28T02:40:14.216361+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"IDEXX enters $1B revolving credit facility with extended maturity and lower rates","bullets":["Fourth amended & restated credit agreement provides $1B unsecured revolver with $250M accordion feature.","Maturity extended to December 9, 2026 (from 2020 agreement's 3-year term).","Interest rate margins reduced; pricing (LIBOR + 0.875–1.375%) based on consolidated leverage ratio.","New borrowers added: IDEXX Laboratories B.V. (Netherlands) and IDEXX Laboratories GmbH (Switzerland).","Proceeds for general corporate purposes; commitment fee on unused portion ranges 0.075–0.250%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-352679","json":"https://secwatch.observer/filing/0001193125-21-352679.json","markdown":"https://secwatch.observer/filing/0001193125-21-352679.md","text":"https://secwatch.observer/filing/0001193125-21-352679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000119312521352679/0001193125-21-352679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000119312521352679/d264618d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:40:14.216361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}